Welcome to our dedicated page for Armata Pharmctcl news (Ticker: ARMP), a resource for investors and traders seeking the latest updates and insights on Armata Pharmctcl stock.
Armata Pharmaceuticals develops pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections. News about ARMP centers on its late clinical-stage phage pipeline, including AP-SA02 for Staphylococcus aureus bacteremia and AP-PA02 for Pseudomonas aeruginosa, FDA designations and regulatory interactions, scientific publications on phage structure, and clinical program updates.
Company updates also cover financial results, research and development spending, grant-supported program activity, credit agreement and warrant amendments with Innoviva-related entities, and board or annual-meeting governance matters. Armata describes in-house phage-specific cGMP manufacturing as part of its development model.
Armata Pharmaceuticals (NYSE American: ARMP) reported first quarter 2026 results and a corporate update. Grant revenue rose to $0.8 million, R&D expenses to $6.1 million, G&A to $3.5 million, and loss from operations to $8.8 million. Net loss was $115.3 million versus $6.5 million a year earlier.
The company is preparing a Phase 3 AP-SA02 study in complicated S. aureus bacteremia, targeting initiation in the second half of 2026. AP-SA02 received FDA Fast Track and QIDP designations. Armata entered a new $25 million secured credit agreement with Innoviva maturing in 2029 and extended prior Innoviva credit maturities to 2027. Cash and equivalents were $4.8 million at March 31, 2026.
Armata Pharmaceuticals (NYSE: ARMP) announced the FDA has granted Fast Track Designation to AP-SA02, its IV multi-phage candidate for adjunct treatment of complicated Staphylococcus aureus bacteremia (MSSA and MRSA). Fast Track allows more frequent FDA engagement, rolling BLA review, and potential eligibility for Accelerated Approval and Priority Review.
The company plans to initiate a Phase 3 superiority study anticipated in the second half of 2026 and expects increased FDA interactions during clinical development.
Armata Pharmaceuticals (ARMP) announced a peer-reviewed publication in Communications Biology titled "Structural atlas of Pakpunavirus P7-1 reveals determinants of virion stability and genome ejection." The paper describes near-atomic cryo-EM structures of phage P7-1, a component of Armata's AP-PA02 phage cocktail.
The study reports dual tail-fiber architecture that locks the tail sheath to preserve stability and a conformational cascade that releases the lock on host recognition. Armata notes AP-PA02 is being developed for chronic Pseudomonas aeruginosa respiratory infections and has completed two Phase 2 trials, SWARM-P.a. and Tailwind.
Armata Pharmaceuticals (NYSE American: ARMP) appointed Daniel B. Gilmer, Ph.D. to its Board of Directors, effective April 24, 2026. Dr. Gilmer currently serves at Pfizer and has experience leading commercial launches, quality oversight for 50+ U.S. brands, and advancing anti-infective programs including work on PAXLOVID and phage-related research.
The appointment adds commercial and access expertise intended to support Armata's late clinical-stage, bacteriophage therapeutic pipeline against antibiotic-resistant infections.
Armata Pharmaceuticals (NYSE American: ARMP) reported fourth-quarter and full-year 2025 results for the period ended December 31, 2025. Key fourth-quarter figures include a net loss of $124.3 million (loss per share $(3.42)), cash and equivalents of $14.1 million, grant revenue of $1.1 million, and R&D expense of approximately $6.1 million.
The quarter included a $105.8 million non-cash fair-value loss on a convertible loan and a $5.4 million impairment on leased facilities. Debt maturities were extended to June 1, 2027 and Innoviva warrants were amended to expire January 26, 2031. Auditor included a going-concern explanatory paragraph.
Armata Pharmaceuticals (NYSE American: ARMP) delayed its Q4 and full‑year 2025 financial results and expects to file its Form 10‑K on or before March 31, 2026. The company received QIDP designation for AP‑SA02 and completed an End‑of‑Phase 2 response enabling a planned Phase 3 superiority trial anticipated to start in H2 2026. Armata commissioned a 56,000 sq ft cGMP facility in Los Angeles with full production runs completed. Phase 2a diSArm data presented at IDWeek 2025 showed higher early cure rates and favorable tolerability for AP‑SA02 versus BAT.
Armata Pharmaceuticals (NYSE: ARMP) announced that the FDA granted QIDP designation to AP-SA02 for intravenous adjunct treatment of complicated bacteremia caused by MSSA or MRSA on February 23, 2026. The designation makes AP-SA02 eligible for five additional years of Hatch-Waxman market exclusivity and potential Fast Track, priority and rolling review. Armata plans to request Fast Track and to initiate a Phase 3 superiority study in H2 2026.
Armata Pharmaceuticals (NYSE: ARMP) received an End-of-Phase 2 written response from the FDA and the agency agreed that data from Armata's Phase 2a diSArm study support advancing AP-SA02 into a Phase 3 superiority study in complicated Staphylococcus aureus bacteremia. The company plans to initiate the Phase 3 study in the second half of 2026 and is addressing FDA comments on CMC, clinical design, and BLA recommendations. Armata has submitted a request for QIDP designation and highlighted Phase 2a results announced in May 2025 and presented at IDWeek 2025.
Armata Pharmaceuticals (NYSE: ARMP) received an End-of-Phase 2 written response from the FDA confirming that safety and efficacy data from its Phase 2a diSArm study support advancing IV AP-SA02 into a Phase 3 superiority study for complicated Staphylococcus aureus bacteremia. The Phase 3 trial is anticipated to initiate in the second half of 2026 and will test AP-SA02’s superiority versus standard of care, with primary endpoints at end of best available antibiotic therapy and at Day 28. The FDA provided guidance on study design, CMC, BLA expectations, and encouraged a QIDP request; Armata has submitted a QIDP request and is addressing FDA comments.
Armata Pharmaceuticals (NYSE American: ARMP) will host a KOL webinar on November 25, 2025 at 10:00am EST featuring Dr. Vance G. Fowler Jr. on complicated S. aureus bacteremia and Armata's phage therapy AP-SA02.
The company highlighted positive Phase 1b/2a diSArm results presented at IDWeek 2025 showing AP-SA02 plus best available antibiotic therapy produced a higher, earlier cure rate at Test of Cure and a 100% response without relapse at TOC and 28 days later (EOS) versus ~25% lack of response/relapse for placebo plus BAT. AP-SA02 was reported well-tolerated with efficacy against MRSA and MSSA.